These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19746411)

  • 1. Re: Acknowledgement of human bioequivalency of matrix's lopinavir-ritonavir formulation to Kaletra, comment to article on Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model, by Garren et al.
    Rackley RJ
    J Pharm Sci; 2010 Feb; 99(2):568-71; author reply 574. PubMed ID: 19746411
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to the comparison of generic ritonavir (Ritomune, Cipla) and lopinavir/ritonavir tablets (Lopimune, Cipla) and the Abbott brand (Norvir soft-gel capsules and Kaletra tablets).
    Chachad S; Gogtay J; Malhotra G; Purandare S
    J Pharm Sci; 2010 Feb; 99(2):572-3; author reply 574. PubMed ID: 19718766
    [No Abstract]   [Full Text] [Related]  

  • 3. Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model.
    Garren KW; Rahim S; Marsh K; Morris JB
    J Pharm Sci; 2010 Feb; 99(2):626-31. PubMed ID: 19230020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.
    van der Lugt J; Lange J; Avihingsanon A; Ananworanich J; Sealoo S; Burger D; Gorowara M; Phanuphak P; Ruxrungtham K
    Antivir Ther; 2009; 14(7):1001-4. PubMed ID: 19918104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation.
    Hull MW; Harris M; Lima V; Guillemi S; Harrigan PR; Montaner JS
    J Clin Pharmacol; 2009 Feb; 49(2):155-61. PubMed ID: 19179294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.
    Klein CE; Chiu YL; Awni W; Zhu T; Heuser RS; Doan T; Breitenbach J; Morris JB; Brun SC; Hanna GJ
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):401-10. PubMed ID: 17224848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation.
    Prescrire Int; 2007 Aug; 16(90):148. PubMed ID: 17724839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
    Crommentuyn KM; Kappelhoff BS; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
    Br J Clin Pharmacol; 2005 Oct; 60(4):378-89. PubMed ID: 16187970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
    van der Lee M; Verweel G; de Groot R; Burger D
    Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.
    TreatmentUpdate; 2008 Mar; 20(2):5-6. PubMed ID: 18661644
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics of two generic co-formulations of lopinavir/ritonavir for HIV-infected children: a pilot study of paediatric Lopimune versus the branded product in healthy adult volunteers.
    de Kanter CT; Colbers EP; Fillekes Q; Hoitsma A; Burger DM
    J Antimicrob Chemother; 2010 Mar; 65(3):538-42. PubMed ID: 20056686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in lopinavir plasma concentrations comparing Kaletra film coated tablets and soft gelatine capsules that result in various lipid abnormalities.
    Morello J; Soriano V; Blanco F; Rubio AJ; Jiménez-Nácher I; Rodríguez-Nóvoa S
    Drug Metab Lett; 2009 Apr; 3(2):67-9. PubMed ID: 19601866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
    Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ
    J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioequivalence study of two fixed dose combination tablet formulations of lopinavir and ritonavir in healthy volunteers.
    Chachad S; Lulla A; Malhotra G; Purandare S
    Arzneimittelforschung; 2009; 59(5):263-8. PubMed ID: 19537528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications.
    la Porte CJ; Schippers EF; van der Ende ME; Koopmans PP; Blok WL; Kauffmann RH; Kroon FP; Burger DM
    AIDS; 2005 Jul; 19(10):1105-7. PubMed ID: 15958844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.
    Dingemanse J; van Giersbergen PL; Patat A; Nilsson PN
    Antivir Ther; 2010; 15(2):157-63. PubMed ID: 20386070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily.
    Ramautarsing RA; van der Lugt J; Gorowara M; Wongsabut J; Khongpetch C; Phanuphak P; Ananworanich J; Lange JM; Burger DM; Ruxrungtham K; Avihingsanon A
    J Acquir Immune Defic Syndr; 2012 Jan; 59(1):55-8. PubMed ID: 22027875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment on: Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
    Neely MN; Rakhmanina NY
    J Antimicrob Chemother; 2010 Apr; 65(4):808-9; author reply 809-10. PubMed ID: 20086000
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative Bioavailability of Two Formulations of Biopharmaceutical Classification System (BCS) Class IV Drugs: A Case Study of Lopinavir/Ritonavir.
    Saeed AM; Schmidt JM; Munasinghe WP; Vallabh BK; Jarvis MF; Morris JB; Mostafa NM
    J Pharm Sci; 2021 Dec; 110(12):3963-3968. PubMed ID: 34530003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.